Advertisement
BIO vs DHR
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- Danaher (DHR) has outperformed BIO year-to-date, with returns of approximately 23% compared to BIO's 16%.
- BIO reported first-quarter 2026 revenue growth of 1.1% but missed earnings estimates, leading to a lowered full-year outlook and recent stock price decline.
- DHR delivered modest core revenue growth in Q1 2026 with strong margins and is advancing a major acquisition of Masimo, supported by debt financing.
- DHR's market capitalization stands at over $124 billion, dwarfing BIO's roughly $7 billion, reflecting greater scale and diversification.
- Both companies operate in life sciences and diagnostics, but DHR benefits from its Danaher Business System for operational efficiency and growth.
Introduction
Bio-Rad Laboratories (BIO) and Danaher (DHR) are prominent players in the life sciences and clinical diagnostics sectors, making them compelling comparables for investors tracking healthcare innovation and bioprocessing trends. This analysis examines their recent market performance, financial metrics, and strategic positioning amid evolving demand for research tools and diagnostic solutions. Traders seeking exposure to biotechnology growth or relative value opportunities in medtech will find insights into momentum shifts, valuation contrasts, and sector dynamics relevant for portfolio decisions.
BIO Overview and Recent Performance
Bio-Rad Laboratories (BIO) develops, manufactures, and markets products for life science research and clinical diagnostics, spanning reagents, instruments, and software for applications like PCR and chromatography. In recent market activity, the stock has faced pressure following first-quarter 2026 results, which showed net sales of $592.1 million, up 1.1% year-over-year but below earnings expectations with a negative surprise on EPS. Management cited challenges in process chromatography and lowered the full-year currency-neutral revenue growth outlook to -3% to +0.5%, contributing to heightened volatility and a pullback from 52-week highs near $343. Sentiment reflects concerns over muted growth in life sciences amid broader biopharma funding caution, though a trailing P/E ratio (price-to-earnings ratio) around 10 suggests relative value.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a global science and technology conglomerate focused on life sciences, diagnostics, and biotechnology, leveraging its proprietary Danaher Business System (DBS)—a continuous improvement framework—for operational excellence and acquisitions. Recent weeks have seen steady performance, buoyed by first-quarter 2026 sales around $6 billion with 0.5% core growth and robust 60.3% gross margins, alongside strong adjusted EPS. The company is raising multi-billion euro debt to fund its acquisition of Masimo, signaling confidence in expanding diagnostics capabilities. Year-to-date gains of 23% outpace peers, supported by resilience in bioprocessing despite market headwinds, with shares trading below analyst targets amid a forward P/E of about 21.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from its library of 351 AI trading bots, which generate real-time signals for stocks, ETFs, and crypto across diverse strategies, timeframes, and tickers. These bots excel in volatile conditions, showcasing annualized returns from +23.67% to +164.21%, win rates of 51% to 88%, profit factors up to 11.70, and trade durations from 15 hours to 50 days. Examples include semiconductor-focused bots with +68% to +98% returns on tickers like NVDA and ASML, volatility plays yielding +164% on nuclear/energy names, and small-cap strategies at +94%. Selected for current market suitability, they offer customizable risk management like take-profit/stop-loss corridors. Explore these high-performing options to enhance your trading edge.
Head-to-Head Comparison
Bio-Rad Laboratories (BIO) maintains a focused model on life science tools and diagnostics, emphasizing organic innovation but grappling with slower growth drivers like biopharma R&D spending. In contrast, Danaher (DHR) pursues a diversified, acquisition-heavy approach via DBS, fueling expansion in high-margin areas like bioprocessing and advanced diagnostics. Recent momentum favors DHR with superior YTD returns and stability versus BIO's post-earnings dip. Risk profiles differ: BIO faces execution hurdles in chromatography (20% debt-to-equity), while DHR's scale mitigates volatility despite leverage for deals. Both share sector exposure to healthcare demand, but DHR commands premium valuations (5x sales multiple vs. BIO's 3x) on stronger profitability and catalysts like Masimo integration.
Tickeron AI Verdict
Tickeron's AI models currently lean toward DHR over BIO, citing greater trend consistency, market-leading scale, and near-term catalysts such as the Masimo acquisition amid resilient diagnostics demand. DHR's higher stability and relative positioning suggest probabilistic outperformance in the prevailing environment, though BIO offers value for recovery plays if guidance improves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Buy and DHR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 3 TA indicator(s) are bullish while DHR’s TA Score has 5 bullish TA indicator(s).
- BIO’s TA Score: 3 bullish, 7 bearish.
- DHR’s TA Score: 5 bullish, 5 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -2.82% price change this week, while DHR (@Medical Specialties) price change was -1.61% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.45%. For the same industry, the average monthly price growth was -3.28%, and the average quarterly price growth was -15.87%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.70%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was -3.13%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
DHR is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Medical/Nursing Services (+0.45% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.70% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | DHR | BIO / DHR | |
| Capitalization | 7.64B | 126B | 6% |
| EBITDA | 440M | 7.08B | 6% |
| Gain YTD | -7.221 | -21.995 | 33% |
| P/E Ratio | 46.77 | 34.53 | 135% |
| Revenue | 2.59B | 24.8B | 10% |
| Total Cash | 1.57B | 5.7B | 27% |
| Total Debt | 1.38B | 18.5B | 7% |
BIO | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 80 | |
PRICE GROWTH RATING 1..100 | 52 | 60 | |
P/E GROWTH RATING 1..100 | 13 | 60 | |
SEASONALITY SCORE 1..100 | 90 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (10) in the Medical Specialties industry is significantly better than the same rating for BIO (83). This means that DHR’s stock grew significantly faster than BIO’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
DHR's SMR Rating (80) in the Medical Specialties industry is in the same range as BIO (90). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (52) in the Medical Specialties industry is in the same range as DHR (60). This means that BIO’s stock grew similarly to DHR’s over the last 12 months.
BIO's P/E Growth Rating (13) in the Medical Specialties industry is somewhat better than the same rating for DHR (60). This means that BIO’s stock grew somewhat faster than DHR’s over the last 12 months.
| BIO | DHR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 56% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 54% |
| Advances ODDS (%) | 8 days ago 66% | 8 days ago 54% |
| Declines ODDS (%) | 2 days ago 68% | 6 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 50% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +0.58% | ||
| TMO - DHR | 77% Closely correlated | -0.13% | ||
| A - DHR | 73% Closely correlated | -0.45% | ||
| RGEN - DHR | 68% Closely correlated | -4.05% | ||
| RVTY - DHR | 64% Loosely correlated | -0.96% | ||
| BIO - DHR | 64% Loosely correlated | -0.47% | ||
More | ||||